What are chemokine receptors, and how do they modulate pain?
Chemokine receptor type 2 is a chemokine receptor that mediates monocyte chemotaxis. Antagonism results in a reduced monocyte infiltration and is thought to have potential in disease, such as rheumatoid arthritis and other autoimmune diseases. However, there was a recent negative phase II posttraumatic neuralgia study by AstraZeneca, placing further development in question. Although there were trends favoring the primary efficacy endpoint of the Neuropathic Pain Symptom Inventory score, it did not reach significance.
